Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal diseases

- PMLiVE

MSD’s Keytruda wins bladder cancer indication in Japan

Becomes first anti-PD1 approved in the country for previously treated UC

- PMLiVE

MSD supports Jabs for the Boys campaign

Awards HPV Action an educational grant for its HPV awareness work

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

- PMLiVE

MSD to create strong UK discovery centre in London

The pharma group aims to start operations by 2020

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

- PMLiVE

CHMP backs MSD’s CMV infection treatment

Prevymis is set to be available as an injectable and tablets

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

MSD touts Keytruda first-line promise in NSCLC

Says patients on the drug more than doubled median OS compared to chemo

- PMLiVE

MSD’s Keytruda wins new bladder cancer indication in Europe

Will treat locally advanced or mUC patients

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

- PMLiVE

Merck CEO resigns from Trump post in Charlottesville protest

Frazier leaves the Manufacturing Council but J&J’s Gorksy remains for now

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links